Navigation Links
Anti-clotting agent helps reduce the incidence and impact of stent thrombosis during PCI
Date:3/27/2014

WASHINGTON, DC March 27, 2014 A new angiographic analysis of the CHAMPION PHOENIX trial examined the incidence and impact of stent thrombosis (ST) in patients undergoing percutaneous coronary intervention (PCI). Results of the study were released today and will be presented March 30 at the American College of Cardiology 63rd Annual Scientific Session.

CHAMPION PHOENIX was a prospective, double-blind, active-controlled trial which randomized 11,145 patients to receive intravenous cangrelor or oral clopidogrel administered at the time of PCI. In a previous analysis presented at TCT 2013 and published in the Journal of the American College of Cardiology, cangrelor significantly reduced periprocedural and 30-day ischemic events in patients undergoing PCI.

In this new analysis, an independent core laboratory (CRF) blinded to the treatment performed the angiographic analysis of 10,939 of the randomized patients. Stent thrombosis was defined as the occurrence of either intraprocedural ST (IPST) or ARC defined ST (definite or probable). Adverse events were adjudicated by an independent clinical events committee.

ST occurred in 120 patients (1.1 percent) at 48 hours and in 175 patients (1.6 percent) at 30 days. The occurrence of ST at 48 hours and 30 days was associated with a marked increase in 30-day mortality (OR [95%CI] = 15.3 [8.6, 27.2], p<0.001; and 55.2 [36.6, 83.3] p<0.001, respectively). IPST, ARC acute ST (≤24 hrs), and ARC subacute ST (1-30 days) occurred in 89 (0.8 percent), 32 (0.3 percent), and 60 (0.5 percent) patients respectively. Each type of ST was also associated with an increase in 30-day mortality (IPST: 17.4 [8.4, 36.1], p<0.001, ARC acute ST: 43.3 [18.1, 103.5], p<0.001, ARC sub-acute ST: 189.1, [107.9, 331.4], p<0.001).

"Regardless of the exact type of stent thrombosis, it remains associated with a high rate of death," stated Deepak L. Bhatt, MD, MPH, Executive Director of Interventional Cardiovascular Programs at Brigham and Women's Hospital Heart & Vascular Center, Professor of Medicine at Harvard Medical School, and Co-Chair of the CHAMPION program.

Cangrelor was associated with a significant reduction in 48-hour (0.8 vs. 1.4 percent, p=0.01) and 30-day ST (1.3 vs. 1.9 percent, p=0.01), compared with clopidogrel. Cangrelor also had consistent effect in IPST (0.6 vs. 1.0 percent, p=0.04), acute ARC ST (0.2 vs. 0.4 percent, p=0.8), and sub-acute ARC ST (0.5 vs. 0.6 percent, p=0.60). After multivariable analysis, the use of cangrelor was identified as an independent predictor of freedom of ST at 30 days.

"The benefits of cangrelor were consistent across all these different categories of stent thrombosis," stated Robert A. Harrington, MD, Chairman of Medicine and Bloomfield Professor of Medicine at Stanford University, and Co-Chair of the CHAMPION program.

"In the large-scale CHAMPION PHOENIX trial, the occurrence of stent thrombosis was strongly associated with increased mortality. Cangrelor use resulted in a significant reduction in ST, with consistent outcomes on intraprocedural, and outside the cath lab acute and sub-acute ARC defined ST," stated lead investigator Philippe Gnreux, MD. Dr. Gnreux is Director of the Angiographic Core Laboratory at the CRF Clinical Trials Center. The CRF Angiographic Core Lab conducted the analyses.


'/>"/>

Contact: Judy Romero
jromero@crf.org
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. Anti-clotting drugs yield similar results
2. Anti-clotting therapy may be used too often following orthopaedic surgery or trauma
3. Discovery could lead to anti-clotting drugs with less risk of bleeding
4. Pradaxa Bleeding Allegations Lawyer: Resource4thePeople Reports New Study May Produce Treatment to Reverse Anti-Clotting Medication Effects
5. Pig stomach mucins are effective as anti-viral agents for consumer products
6. Imaging agents predict breast cancer response to endocrine therapy
7. Difficult to diagnose cases of infectious endocarditis solved with SPECT/CT imaging agent
8. New substances 15,000 times more effective in destroying chemical warfare agents
9. Therapy combining exercise and neuroprotective agent shows promise for stroke victims
10. Scientists ID Cancer-Causing Agent in Smokeless Tobacco
11. Mayo Clinic gets FDA approval for new imaging agent for recurrent prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... (PRWEB) , ... January 21, 2017 , ... ... of its new medical office in Petaluma, located at 167 Lynch Creek Way. ... access to SRO sports medicine and rehabilitation services and on-site x-ray ...
(Date:1/20/2017)... ... 20, 2017 , ... Spectrum Aquatics Launches New ADA Portable Motion Trek BP 300 Lift. Built ... is mounted on wheels, it can be wheeled out of the way and stored when ... the deck. "We have transformed the feedback from customers into specific enhancements and created a ...
(Date:1/20/2017)... ... January 20, 2017 , ... Source Vitál Apothecary, a skin and body ... oils, announced the company had a successful visit to the 2017 ECRM Diet, Vitamin ... companies that work in the nutritional, sports and health industries a chance to meet ...
(Date:1/20/2017)... ... January 20, 2017 , ... Lice Troopers, the lice removal company ... with school-aged children since the holiday season. , “It happens every year around ... sharing hugs and taking photos, which is the head-to-head gateway that lice need to ...
(Date:1/20/2017)... ... January 20, 2017 , ... Michael and Betsy Brauser celebrated 5 years ... Betsy, the clinical trial has been life-saving as she has been on the ... Betsy Brauser was diagnosed with ovarian cancer in 2009. She underwent standard chemotherapy but ...
Breaking Medicine News(10 mins):
(Date:1/20/2017)... , January 20, 2017 Avillion LLP, ... appointment of Mark Weinberg , MD MBA as Chief Medical ... , USA . ... Dr Weinberg has spent more than 17 years ... 20" pharma companies to micro-cap biotech. Over the course of his ...
(Date:1/19/2017)... YORK , Jan. 19, 2017 Report ... Ophthalmic Devices Market? Which areas are going to grow ... potential revenues to 2026, assessing data, trends, opportunities and ... and graphs. Discover the most lucrative areas in the ... lets you assess forecasted sales across the all the ...
(Date:1/19/2017)... 2017 Conference Call and Webcast to Follow ... it will release results for the fourth quarter of 2016 on ... ... call at 4:30 PM ET on Wednesday, February 15, 2017, during ... financial results and other corporate activities. To participate in the conference ...
Breaking Medicine Technology: